Cargando…

Disease severity and minimal clinically important differences in clinical outcome assessments for Alzheimer's disease clinical trials

INTRODUCTION: This study estimated the minimal clinically important difference (MCID) for Mini Mental State Examination, Clinical Dementia Rating Scale sum of boxes, and Functional Activities Questionnaire across the Alzheimer's disease (AD) spectrum. METHODS: Retrospective analysis of the Nati...

Descripción completa

Detalles Bibliográficos
Autores principales:	Andrews, J. Scott, Desai, Urvi, Kirson, Noam Y., Zichlin, Miriam L., Ball, Daniel E., Matthews, Brandy R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2019
Materias:	Featured Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6690415/ https://www.ncbi.nlm.nih.gov/pubmed/31417957 http://dx.doi.org/10.1016/j.trci.2019.06.005

Ejemplares similares

Response to van Dyck, O'Dell, & Mecca letter to the editor regarding Andrews et al. (2019)
por: Andrews, J. Scott, et al.
Publicado: (2023)

Disease severity at the time of initial cognitive assessment is related to prior health‐care resource use burden
por: Desai, Urvi, et al.
Publicado: (2020)

Patient Characteristics and Outcomes Associated with Receiving an Earlier Versus Later Diagnosis of Probable Alzheimer’s Disease
por: Kirson, Noam Y., et al.
Publicado: (2017)

Trends in health service use and potentially avoidable hospitalizations before Alzheimer's disease diagnosis: A matched, retrospective study of US Medicare beneficiaries
por: Desai, Urvi, et al.
Publicado: (2019)

Assessing the economic burden of Alzheimer’s disease patients first diagnosed by specialists
por: Kirson, Noam Y., et al.
Publicado: (2016)

Disease severity and minimal clinically important differences in clinical outcome assessments for Alzheimer's disease clinical trials
por: Van Dyck, Christopher H., et al.
Publicado: (2023)

Disease Progression and Longitudinal Clinical Outcomes of Lewy Body Dementia in the NACC Database
por: Chandler, Julie, et al.
Publicado: (2022)

Progranulin mutations in clinical and neuropathological Alzheimer's disease
por: Vardarajan, Badri N., et al.
Publicado: (2022)

Clinical and cognitive characteristics of preclinical Alzheimer's disease in the Japanese Alzheimer's Disease Neuroimaging Initiative cohort
por: Ihara, Ryoko, et al.
Publicado: (2018)

Cost-Effectiveness of Apomorphine Sublingual Film as an “On-Demand” Treatment for “OFF” Episodes in Patients with Parkinson’s Disease
por: Thach, Andrew, et al.
Publicado: (2021)

The TOMMORROW study: Design of an Alzheimer's disease delay-of-onset clinical trial
por: Burns, Daniel K., et al.
Publicado: (2019)

Measuring informed consent capacity in an Alzheimer's disease clinical trial
por: Guarino, Peter D., et al.
Publicado: (2016)

Enrichment factors for clinical trials in mild-to-moderate Alzheimer's disease
por: Ballard, Clive, et al.
Publicado: (2019)

Analyses of natural courses of Japanese patients with Alzheimer's disease using placebo data from placebo-controlled, randomized clinical trials: Japanese Study on the Estimation of Clinical course of Alzheimer's disease
por: Watanabe, Mitsunori, et al.
Publicado: (2019)

African Americans are less likely to enroll in preclinical Alzheimer's disease clinical trials
por: Zhou, Yan, et al.
Publicado: (2016)

Power analysis to detect treatment effects in longitudinal clinical trials for Alzheimer's disease
por: Huang, Zhiyue, et al.
Publicado: (2017)

An examination of a novel multipanel of CSF biomarkers in the Alzheimer's disease clinical and pathological continuum
por: Van Hulle, Carol, et al.
Publicado: (2020)

Clinical reporting following the quantification of cerebrospinal fluid biomarkers in Alzheimer's disease: An international overview
por: Delaby, Constance, et al.
Publicado: (2021)

Baseline demographic, clinical, and cognitive characteristics of the Alzheimer's Prevention Initiative (API) Autosomal‐Dominant Alzheimer's Disease Colombia Trial
por: Rios‐Romenets, Silvia, et al.
Publicado: (2020)

Using baseline cognitive severity for enriching Alzheimer's disease clinical trials: How does Mini-Mental State Examination predict rate of change?
por: Kennedy, Richard E., et al.
Publicado: (2015)

Dissociation of Down syndrome and Alzheimer's disease effects with imaging
por: Matthews, Dawn C., et al.
Publicado: (2016)

Excess Costs Associated with Possible Misdiagnosis of Alzheimer’s Disease Among Patients with Vascular Dementia in a UK CPRD Population
por: Happich, Michael, et al.
Publicado: (2016)

Preclinical and clinical biomarker studies of CT1812: A novel approach to Alzheimer's disease modification
por: Izzo, Nicholas J., et al.
Publicado: (2021)

Results and insights from a phase I clinical trial of Lomecel‐B for Alzheimer's disease
por: Brody, Mark, et al.
Publicado: (2022)

The Importance of Considering Olfactory Dysfunction During the COVID-19 Pandemic and in Clinical Practice
por: Desai, Mauli, et al.
Publicado: (2021)

Effect of sample size re-estimation in adaptive clinical trials for Alzheimer's disease and mild cognitive impairment
por: Wang, Guoqiao, et al.
Publicado: (2015)

Extracellular vesicle biomarkers of Alzheimer's disease associated with sub‐clinical cognitive decline in late middle age
por: Eren, Erden, et al.
Publicado: (2020)

Head‐to‐head comparison of clinical performance of CSF phospho‐tau T181 and T217 biomarkers for Alzheimer's disease diagnosis
por: Karikari, Thomas K., et al.
Publicado: (2020)

Meaningful benefit and minimal clinically important difference (MCID) in Alzheimer's disease: Open peer commentary
por: Cummings, Jeffrey
Publicado: (2023)

A randomized, controlled clinical trial of plasma exchange with albumin replacement for Alzheimer's disease: Primary results of the AMBAR Study
por: Boada, Mercè, et al.
Publicado: (2020)

Development of Written Materials for Participants in an Alzheimer's Disease and Related Dementias Screening Trial
por: Head, Katharine J, et al.
Publicado: (2022)

Reliability of coded data to identify earliest indications of cognitive decline, cognitive evaluation and Alzheimer’s disease diagnosis: a pilot study in England
por: Dell’Agnello, Grazia, et al.
Publicado: (2018)

A simulation study comparing slope model with mixed-model repeated measure to assess cognitive data in clinical trials of Alzheimer's disease
por: Chen, Yun-Fei, et al.
Publicado: (2018)

Clinical governance for the dental team
por: Rashid Chawdhary, Iqra
Publicado: (2020)

Alzheimer's Prevention Initiative Generation Program: Development of an APOE genetic counseling and disclosure process in the context of clinical trials
por: Langlois, Carolyn M., et al.
Publicado: (2019)

Two-period linear mixed effects models to analyze clinical trials with run-in data when the primary outcome is continuous: Applications to Alzheimer's disease
por: Wang, Guoqiao, et al.
Publicado: (2019)

Stereotactic brain injection of human umbilical cord blood mesenchymal stem cells in patients with Alzheimer's disease dementia: A phase 1 clinical trial
por: Kim, Hee Jin, et al.
Publicado: (2015)

A phase 1 clinical trial of the sigma-2 receptor complex allosteric antagonist CT1812, a novel therapeutic candidate for Alzheimer's disease
por: Grundman, Michael, et al.
Publicado: (2019)

Nerve growth factor (NGF) pathway biomarkers in Down syndrome prior to and after the onset of clinical Alzheimer's disease: A paired CSF and plasma study
por: Pentz, Rowan, et al.
Publicado: (2020)

Effectiveness of a Telephone-Based Motivational Intervention for Smoking Cessation in Patients With Crohn Disease: A Randomized, Open-Label, Controlled Clinical Trial
por: Navarro Correal, Ester, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_35gibldrifgfdqiq4ldh2fmup6